[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643424":3},{"organization":4,"outcomesModule":7,"designInfo":69,"detailedDescription":11,"studyPopulation":11,"armGroups":76,"interventions":88,"overallOfficials":97,"centralContacts":101,"locations":110,"responsibleParty":127,"collaborators":129,"id":134,"slug":135,"hasResults":136,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":143,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":11,"studyType":149,"phases":150,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":113,"whyStopped":11,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"Göteborg University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":56},[9,13],{"measure":10,"description":11,"timeFrame":12},"Leptin",null,"Change from baseline to 6 weeks",{"measure":14,"description":15,"timeFrame":12},"ApoB","Apolipoprotein B",[17,19,20,24,27,29,32,35,39,43,47,50,53],{"measure":10,"description":11,"timeFrame":18},"Change from baseline to 2 weeks",{"measure":14,"description":15,"timeFrame":18},{"measure":21,"description":22,"timeFrame":23},"Ghrelin, PYY, cholecystokinin, insulin","Other appetite-regulating hormones","Change from baseline to 2 weeks and from baseline to 6 weeks",{"measure":25,"description":26,"timeFrame":23},"Blood lipid profile","ApoA1, LDL, HDL, VLDL, total cholesterol, triglycerides, Lp(a)",{"measure":28,"description":11,"timeFrame":23},"Body weight",{"measure":30,"description":31,"timeFrame":23},"Body composition","Fat mass and fat-free mass",{"measure":33,"description":34,"timeFrame":23},"Blood pressure","Diastolic and systolic blood pressure",{"measure":36,"description":37,"timeFrame":38},"Biomarkers of ultra-processed food intake","Measured in blood and urine","At 2 weeks and at 6 weeks",{"measure":40,"description":41,"timeFrame":42},"Gut microbiome","Change in gut microbial composition and diversity (alpha- and beta)","At 2 weeks and 6 weeks",{"measure":44,"description":45,"timeFrame":46},"Glucose","Glucose, measured by continuous blood glucose monitoring","Continuous during the first 2 weeks",{"measure":48,"description":49,"timeFrame":23},"Energy intake","Ad libitum energy intake at standardized test meal",{"measure":51,"description":52,"timeFrame":23},"Subjective appetite","Self-rated appetite before and after a standardized test meal",{"measure":54,"description":55,"timeFrame":23},"Food cravings and eating behavior","Control of Eating Questionnaire, Three Factor Eating Questionnaire, Power of Food Scale",[57,60,63,66],{"measure":58,"description":59,"timeFrame":42},"Oral microbiome","Change in oral microbial composition",{"measure":61,"description":62,"timeFrame":42},"Compliance","Compliance assessed by food records",{"measure":64,"description":65,"timeFrame":23},"Sleep","Pittsburgh Sleep Quality Index",{"measure":67,"description":68,"timeFrame":23},"Well-being","WHO-5 Wellbeing Index",{"allocation":70,"interventionModel":71,"interventionModelDescription":11,"primaryPurpose":72,"observationalModel":11,"timePerspective":11,"maskingInfo":73},"RANDOMIZED","CROSSOVER","PREVENTION",{"masking":74,"maskingDescription":75,"whoMasked":11},"NONE","Those conducting laboratory analyses will be blinded to the allocation of participants.",[77,84],{"label":78,"type":79,"description":80,"interventionNames":81},"Sequence 1: high UPF, low UPF","EXPERIMENTAL","Diet high in UPF, followed by a diet low in UPF",[82,83],"Other: Diet high in UPF","Other: Diet low in UPF",{"label":85,"type":79,"description":86,"interventionNames":87},"Sequence 2: low UPF, high UPF","Diet low in UPF, followed by a diet high in UPF",[82,83],[89,93],{"type":6,"name":90,"description":91,"armGroupLabels":92,"otherNames":11},"Diet high in UPF","Diet high in Ultra-processed food (\\>80 % of total energy intake)",[78,85],{"type":6,"name":94,"description":95,"armGroupLabels":96,"otherNames":11},"Diet low in UPF","Diet low in Ultra-processed food (\\\u003C20 % of total energy intake)",[78,85],[98],{"name":99,"affiliation":5,"role":100},"Linnea Bärebring, PhD, Associate professor","PRINCIPAL_INVESTIGATOR",[102,107],{"name":99,"role":103,"phone":104,"phoneExt":105,"email":106},"CONTACT","0317863771","+46","linnea.barebring@gu.se",{"name":108,"role":103,"phone":11,"phoneExt":11,"email":109},"Therese Karlsson, PhD, Associate professor","therese.karlsson@gu.se",[111],{"facility":112,"status":113,"city":114,"state":11,"zip":115,"country":116,"countryCode":117,"cosmosGeoPoint":118,"geoPoint":123,"contacts":124},"University of Gothenburg","RECRUITING","Gothenburg","40530","Sweden","SE",{"type":119,"coordinates":120},"Point",[121,122],11.96679,57.70716,{"lat":122,"lon":121},[125,126],{"name":99,"role":103,"phone":104,"phoneExt":105,"email":106},{"name":108,"role":103,"phone":11,"phoneExt":11,"email":11},{"type":128,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[130,132],{"name":131,"class":6},"Chalmers University of Technology",{"name":133,"class":6},"Karolinska Institutet","100643424","health-effects-of-ultra-processed-food-intake-100643424",false,"NCT07634159","Health Effects of Ultra-processed Food Intake","Health Effects of Ultra-processed Food Intake: a Randomized Crossover Feeding Study","UPFront","Inclusion Criteria:\n\n* Age 20-60 years\n* Weight stable (less than 5% weight change in the past 3 months)\n* No plans to change weight\n* Willing to eat the study diet and a mixed diet\n* Habitually eats breakfast, lunch and dinner\n* Has provided informed consent to participate in the study\n\nExclusion Criteria:\n\n* Allergy or intolerance to foods included in the study. Participants with lactose intolerance treated with lactase may participate if they take enzymes.\n* BMI \\\u003C18.5 or \\>35 kg\u002Fm²\n* \\>8h\u002Fweek of intense physical activity\n* Use of medications known to significantly affect appetite (e.g., oral corticosteroids, antipsychotic medications, or GLP-1 receptor agonists)\n* Use of lipid-lowering medications (e.g., statins or PCSK9 inhibitors)\n* Diagnosed diabetes or capillary blood glucose at or above 12.2 mmol\u002FL\n* Disease associated with malabsorption (e.g., inflammatory bowel disease or celiac disease)\n* Previous bariatric surgery\n* Established cardiovascular disease (heart failure, myocardial infarction, or stroke) or cancer\n* Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study\n* Deemed likely to have poor adherence",true,"ALL","20 Years","60 Years",{"count":147,"type":148},40,"ESTIMATED","INTERVENTIONAL",[151],"NA","Ultra-processed food (UPF) intake has been related to negative health effects and increased energy intake in previous intervention studies. Thus, previous studies have seen weight gain from higher UPF intake which obscures the potential to see effects on cardiometabolic biomarkers, independent of weight changes. The overall aim of this project is to study the causal effects of a high UPF diet, compared to a nutrient-matched low UPF diet, on appetite and cardiometabolic health in a weight-stable context.",[154,155,156],"Cardiometabolic Risk Factors","Microbiota","Diet Interventions",[158],"Ultra-processed food","2026-08-21",{"date":161,"type":162},"2026-08-24","ACTUAL",{"date":164,"type":162},"2026-06-25",{"date":166,"type":148},"2027-12",{"name":5,"class":6},1]